Table 2. Growth characteristics of patient derived cervical cancer xenografts.
| Sample | FIGO stage | Histological type | Graft growth | Time in vivo for serial xenografts (days) |
Tumour volume of serial xenografts (mm3) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First | Second | Third | Fourth | First | Second | Third | Fourth | |||||
| CC1 | 1B1 |
CIN3/WD-SCC | Yes | 184±18 | 126±70.5 | 2250 | ||||||
| CC2 | LG villous adenocarcinoma | Yes | 271±0 | 190±0 | 220 | 562.5 | ||||||
| CC3 | MD SCC | Yes | 195 | 175 | 324 | 2 | ||||||
| CC4 | MD SCC | Yes | 237 | 125±0 | 120 | 1 | ||||||
| CC5 | W-MD SCC | Yes | 231±87.3 | 2 | ||||||||
| CC6 | No | 379 | ||||||||||
| CC7 | 1B2 |
WD SCC | Yes | 90±57 | 70 | |||||||
| CC8 | No | 341 | ||||||||||
| CC9 | MD SCC | Yes | 271±0 | 216±0 | 210 | 12.5±12 | ||||||
| CC10 | 2B | SCC/AIS* | No | 232±45.5 | ||||||||
| CC11 | MD SCC | No | 358 | |||||||||
| CC12 | 3A | PD SCC | Yes | 140±66.7 | 165±3.5 | 175±0 | 126 | 2640 | 128 | 335±162 | 192 | |
| CC13 | MD SCC | Yes | 159±42 | 421 | 4 | 98 | ||||||
| CC14 | 3B | MD SCC | Yes | 98.5±28.2 | 201±1.4 | 189±26.5 | 165±0 | 480±40.0 | 4000 | 3729±2541 | 298±52.5 | |
| Mean ± SEM | 71.4 ± 12.5% | 227±24.3 | 204±38.4 | 189.5 | 145±19.5 | 736±206 | 2064 | 3729 | 244±52.8 | |||